Dechra Pharmaceuticals Zukünftiges Wachstum

Future Kriterienprüfungen 4/6

Dechra Pharmaceuticals wird ein Gewinn- und Umsatzwachstum von 21.2% bzw. 7.2% pro Jahr prognostiziert, während der Gewinn pro Aktie um 21.2% pro Jahr wachsen soll.

Wichtige Informationen

21.2%

Wachstumsrate der Gewinne

21.2%

EPS-Wachstumsrate

Pharmaceuticals Gewinnwachstum	19.5%
Wachstumsrate der Einnahmen	7.2%
Zukünftige Eigenkapitalrendite	n/a
Analystenabdeckung	Good
Zuletzt aktualisiert	17 Apr 2023

Jüngste Aktualisierungen zum künftigen Wachstum

Keine Aktualisierungen

Recent updates

Gewinn- und Umsatzwachstumsprognosen

BMV:DPH N - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (GBP Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
6/30/2025	907	101	143	191	10
6/30/2024	844	84	136	186	11
6/30/2023	781	57	104	146	10
12/31/2022	727	40	45	86	N/A
9/30/2022	704	49	45	105	N/A
6/30/2022	682	58	45	123	N/A
3/31/2022	661	66	48	121	N/A
12/31/2021	641	73	51	119	N/A
9/30/2021	624	64	3	104	N/A
6/30/2021	608	56	-45	89	N/A
3/31/2021	587	50	-45	102	N/A
12/31/2020	566	44	-44	114	N/A
9/30/2020	541	39	7	110	N/A
6/30/2020	515	34	57	106	N/A
3/31/2020	507	31	57	91	N/A
12/31/2019	499	29	57	76	N/A
9/30/2019	490	30	58	79	N/A
6/30/2019	482	31	59	82	N/A
3/31/2019	463	28	61	82	N/A
12/31/2018	444	25	62	81	N/A
9/30/2018	426	30	57	73	N/A
6/30/2018	407	36	51	64	N/A
3/31/2018	394	40	57	69	N/A
12/31/2017	381	43	63	75	N/A
9/30/2017	370	35	65	76	N/A
6/30/2017	359	26	67	77	N/A
3/31/2017	334	19	60	69	N/A
12/31/2016	309	11	54	62	N/A
9/30/2016	278	12	N/A	53	N/A
6/30/2016	248	13	N/A	44	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: DPH NDas prognostizierte Gewinnwachstum (21.2% pro Jahr) liegt über der Sparquote (7.5%).

Ertrag vs. Markt: DPH NDie Erträge des Unternehmens (21.2% pro Jahr) werden voraussichtlich schneller wachsen als der Markt MX (11.5% pro Jahr).

Hohe Wachstumserträge: DPH NEs wird erwartet, dass die Erträge des Unternehmens in den nächsten 3 Jahren erheblich steigen werden.

Einnahmen vs. Markt: DPH NDie Einnahmen des Unternehmens (7.2% pro Jahr) werden voraussichtlich schneller wachsen als der Markt MX (7.2% pro Jahr).

Hohe Wachstumseinnahmen: DPH NDie Einnahmen des Unternehmens (7.2% pro Jahr) werden voraussichtlich langsamer wachsen als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: Unzureichende Daten, um festzustellen, ob die Eigenkapitalrendite von DPH N in 3 Jahren voraussichtlich hoch sein wird

Dechra Pharmaceuticals Zukünftiges Wachstum

Future Kriterienprüfungen 4/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

Dechra Pharmaceuticals Limited agreed to acquire Invetx, Inc. from a group of shareholders for $520 million.

Dechra Pharmaceuticals Limited agreed to acquire Invetx, Inc. from a group of shareholders for $520 million.

Dechra Pharmaceuticals Limited reached agreement in principle to acquire 33.34% stake in STEM Animal Health Inc. for $4.7 million.

Dechra Group Holdings Limited Announces Resignation of Sara Huda as Director

EQT X EUR SCSp and EQT X USD SCSp managed by Eqt Fund Management S.à R.L. and Luxinva SA (the Offerors) completed the acquisition of Dechra Pharmaceuticals PLC (LSE:DPH).

Dechra Pharmaceuticals PLC(LSE:DPH) dropped from FTSE All-Share Index (GBP)

Dechra Pharmaceuticals' Cancellation of Listing and Admission to Trading of Shares Expected on 17 January 2024

Dechra Pharmaceuticals Plc Announces Directorate Change

Dechra Pharmaceuticals Plc Announces Directorate Change

Dechra Pharmaceuticals PLC to Report Fiscal Year 2023 Results on Oct 12, 2023

Dechra Pharmaceuticals PLC(LSE:DPH) dropped from FTSE 250 (Ex Investment Companies) Index (GBP)

Dechra Pharmaceuticals plc Announces Resignation of Ishbel Macpherson as Non-Executive Director

Dechra Pharmaceuticals Intends to Delist from Official List

Less than half of directors are independent

Dechra Pharmaceuticals PLC Appoints Geeta Gopalan as A Non-Executive Director of the Company

Dechra Pharmaceuticals PLC(LSE:DPH) dropped from FTSE 100 Index

Dechra Pharmaceuticals PLC, Annual General Meeting, Oct 19, 2023

Dechra Pharmaceuticals plc Proposes Final Dividend for the Year Ended June 30, 2022

Dechra Pharmaceuticals PLC (LSE:DPH) acquired Med-Pharmex, Inc. from DW Management Services, LLC for $260 million on a debt-free and cash-free basis.

Dechra Pharmaceuticals PLC (LSE : DPH) agreed to acquire Piedmont Animal Health LLC for approximately $210 million.

Less than half of directors are independent

Investor sentiment improved over the past week

Dechra Pharmaceuticals PLC Announces Executive Changes

Investor sentiment deteriorated over the past week

Less than half of directors are independent

Investor sentiment improved over the past week

Non-Executive Chairman recently bought Mex$2.6m worth of stock

Investor sentiment improved over the past week

First half 2022 earnings: Revenues and EPS in line with analyst expectations

Dechra Pharmaceuticals PLC Declares Interim Dividend, Payable on April 7, 2022

Dechra Pharmaceuticals plc Announces Executive Changes

Investor sentiment deteriorated over the past week

Dechra Pharmaceuticals PLC (LSE:DPH) agreed to acquire Worldwide Rights to Verdinexor from Anivive Lifesciences, Inc.

Dechra Pharmaceuticals PLC(LSE:DPH) dropped from FTSE 250 (Ex Investment Companies) Index (GBP)

Non-Executive Director Denise Goode has left the company

Less than half of directors are independent

Upcoming dividend of UK£0.29 per share

Less than half of directors are independent

Non-Executive Director recently bought Mex$178k worth of stock

Full year 2021 earnings released: EPS UK£0.51 (vs UK£0.33 in FY 2020)

Less than half of directors are independent

Board Member recently sold Mex$27m worth of stock

Non-Executive Director recently bought Mex$587k worth of stock

Non-Executive Director recently bought Mex$587k worth of stock

First half 2021 earnings released: EPS UK£0.22 (vs UK£0.13 in 1H 2020)

Akston Biosciences Signs Licensing Agreement with Dechra Pharma for Aks-425C

Dechra Pharmaceuticals PLC, Annual General Meeting, Oct 21, 2021

CEO, MD & Executive Director recently sold Mex$279m worth of stock

Dechra Pharmaceuticals PLC Launches Mirataz

Dechra Pharmaceuticals PLC to Report First Half, 2021 Results on Feb 22, 2021

Non-Executive Director recently bought Mex$712k worth of stock

Independent Non Executive Director recently sold Mex$3.5m worth of stock

Gewinn- und Umsatzwachstumsprognosen

Analystenprognosen zum zukünftigen Wachstum

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Wachstumsunternehmen entdecken